Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15401996 | 1.00 | AKR1C1 (0.39) | AKR1C1KDM4EGAAMAPTMAPK1 | |
| SCHEMBL11481050 | 0.87 | AKR1C1 (0.40) | AKR1C1KDM4EGAAMAPTMAPK1 | |
| SCHEMBL19690120 | 0.80 | HCAR3 (0.45) | AKR1C1GAAALDH1A1 | |
| SCHEMBL19280330 | 0.80 | HCAR3 (0.45) | AKR1C1GAAALDH1A1 | |
| SCHEMBL19701802 | 0.80 | HCAR3 (0.45) | AKR1C1GAAALDH1A1 | |
| SCHEMBL19280315 | 0.80 | HCAR3 (0.45) | AKR1C1GAAALDH1A1 | |
| SCHEMBL20898616 | 0.80 | AKR1C1 (0.40) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL16699326 | 0.79 | KMT2A (0.37) | AKR1C1KDM4EGAAMAPTMAPK1 | |
| SCHEMBL2221 | 0.79 | AKR1C1 (0.55) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL27412387 | 0.78 | HDAC4 (0.37) | AKR1C1KDM4EGAAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694502-B1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11319283-B2 | Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200277252-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-09-03 | — | — | US | disclosed |
| EP-2868660-B1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING AN IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-9375434-B2 | Antitumor effect potentiator composed of imidazooxazine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9289431-B2 | — | — | 2016-03-22 | — | — | US | disclosed |
| EP-2698372-B1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20150164909-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2868660-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-8772283-B2 | Imidazo-oxazine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| EP-2698372-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-20140005185-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164909-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | AKR1C1 543/4885KDM4E 2979/4885GAA 4800/4885 |
| US-11319283-B2 | Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, KYNU | AKR1C1 1340/4885KDM4E 1157/4885GAA 175/4885 |
| US-20140005185-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | IKZF3, IKZF2, IKZF1 | AKR1C1 1906/4885KDM4E 1197/4885GAA 3901/4885 |
| US-20200277252-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | AKR1C1 1122/4885KDM4E 1190/4885GAA 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.